Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Mol Cancer Ther ; 18(10): 1832-1843, 2019 10.
Article in English | MEDLINE | ID: mdl-31350344

ABSTRACT

The FGFR4/FGF19 signaling axis is overactivated in 20% of liver tumors and currently represents a promising targetable signaling mechanism in this cancer type. However, blocking FGFR4 or FGF19 has proven challenging due to its physiological role in suppressing bile acid synthesis which leads to increased toxic bile acid plasma levels upon FGFR4 inhibition. An FGFR4-targeting antibody, U3-1784, was generated in order to investigate its suitability as a cancer treatment without major side effects.U3-1784 is a high-affinity fully human antibody that was obtained by phage display technology and specifically binds to FGFR4. The antibody inhibits cell signaling by competing with various FGFs for their FGFR4 binding site thereby inhibiting receptor activation and downstream signaling via FRS2 and Erk. The inhibitory effect on tumor growth was investigated in 10 different liver cancer models in vivo The antibody specifically slowed tumor growth of models overexpressing FGF19 by up to 90% whereas tumor growth of models not expressing FGF19 was unaffected. In cynomolgus monkeys, intravenous injection of U3-1784 caused elevated serum bile acid and liver enzyme levels indicating potential liver damage. These effects could be completely prevented by the concomitant oral treatment with the bile acid sequestrant colestyramine, which binds and eliminates bile acids in the gut. These results offer a new biomarker-driven treatment modality in liver cancer without toxicity and they suggest a general strategy for avoiding adverse events with FGFR4 inhibitors.


Subject(s)
Antibodies, Monoclonal/toxicity , Antibodies, Monoclonal/therapeutic use , Receptor, Fibroblast Growth Factor, Type 4/immunology , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Cholestyramine Resin/pharmacology , Female , Gene Expression Regulation/drug effects , Humans , Ileum/drug effects , Ileum/metabolism , Liver/drug effects , Liver/metabolism , Mice , Mice, Inbred BALB C , NIH 3T3 Cells , Signal Transduction/drug effects , Sorafenib/pharmacology
2.
World J Gastroenterol ; 21(20): 6384-90, 2015 May 28.
Article in English | MEDLINE | ID: mdl-26034375

ABSTRACT

Patients with metastasized carcinoma of the pancreas have a very poor prognosis, and long-term survival cannot be expected. This case report describes two patients with an initial diagnosis of metastatic pancreatic cancer, both with hepatic metastases and one with an additional peritoneal carcinomatosis. Initially, both patients were treated intravenously with the FOLFIRINOX chemotherapy regimen, consisting of 5-FU, folinic acid, irinotecan and oxaliplatin. Surprisingly, the FOLFIRINOX treatment resulted in complete resolution of the hepatic metastases in both patients, with no lesions detectable by computed tomography scan. Furthermore, treatment response included decreased diameter of the primary tumor in the tail of the pancreas and disappearance of the additional peritoneal carcinomatosis. Both patients were discussed by our multidisciplinary tumor board, which recommended surgical resections of the carcinoma. The R0 resection of the primary tumor was successful in both cases and, interestingly, the resected tissues showed no evidence of the hepatic metastases intraoperatively. In the first case, the patient received a postoperative 6-mo course of adjuvant chemotherapy with gemcitabine. In the second case, the patient continued to receive the FOLFIRINOX regimen for an additional 6 mo postoperatively. At 12 mo after the operation, a nonresectable retroperitoneal lymph node metastasis was detected in the first patient, whereas the second patient remained in complete remission at the time of this report (5 mo after the adjuvant therapy was discontinued). This case report is the first of its kind to describe two cases of hepatic metastatic pancreatic carcinoma that were resectable following treatment with FOLFIRINOX. Further studies are required to examine the role of FOLFIRINOX as a neoadjuvant treatment option in subgroups of patients with initially metastasized pancreatic carcinoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Pancreatic Ductal/therapy , Hepatectomy , Liver Neoplasms/therapy , Neoadjuvant Therapy , Pancreatectomy , Pancreatic Neoplasms/therapy , Aged , Biopsy , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Carcinoma, Pancreatic Ductal/secondary , Chemotherapy, Adjuvant , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Female , Fluorouracil/therapeutic use , Humans , Irinotecan , Leucovorin/therapeutic use , Liver Neoplasms/secondary , Lymph Node Excision , Lymphatic Metastasis , Magnetic Resonance Imaging , Male , Middle Aged , Multimodal Imaging , Neoplasm Staging , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Pancreatic Neoplasms/pathology , Positron-Emission Tomography , Remission Induction , Tomography, X-Ray Computed , Treatment Outcome , Tumor Burden , Gemcitabine
3.
J Inherit Metab Dis ; 38(6): 1075-83, 2015 Nov.
Article in English | MEDLINE | ID: mdl-25896882

ABSTRACT

Glutamine synthetase (GS) deficiency is an ultra-rare inborn error of amino acid metabolism that has been described in only three patients so far. The disease is characterized by neonatal onset of severe encephalopathy, low levels of glutamine in blood and cerebrospinal fluid, chronic moderate hyperammonemia, and an overall poor prognosis in the absence of an effective treatment. Recently, enteral glutamine supplementation was shown to be a safe and effective therapy for this disease but there are no data available on the long-term effects of this intervention. The amino acid glutamine, severely lacking in this disorder, is central to many metabolic pathways in the human organism and is involved in the synthesis of nicotinamide adenine dinucleotide (NAD(+)) starting from tryptophan or niacin as nicotinate, but not nicotinamide. Using fibroblasts, leukocytes, and immortalized peripheral blood stem cells (PBSC) from a patient carrying a GLUL gene point mutation associated with impaired GS activity, we tested whether glutamine deficiency in this patient results in NAD(+) depletion and whether it can be rescued by supplementation with glutamine, nicotinamide or nicotinate. The present study shows that congenital GS deficiency is associated with NAD(+) depletion in fibroblasts, leukocytes and PBSC, which may contribute to the severe clinical phenotype of the disease. Furthermore, it shows that NAD(+) depletion can be rescued by nicotinamide supplementation in fibroblasts and leukocytes, which may open up potential therapeutic options for the treatment of this disorder.


Subject(s)
Amino Acid Metabolism, Inborn Errors/genetics , Glutamate-Ammonia Ligase/deficiency , Glutamine/blood , Hyperammonemia/genetics , NAD/blood , NAD/deficiency , B-Lymphocytes/cytology , Cell Culture Techniques , Dietary Supplements , Fibroblasts/cytology , Glutamate-Ammonia Ligase/genetics , Humans , Point Mutation
4.
Cancer Chemother Pharmacol ; 74(5): 947-54, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25173458

ABSTRACT

PURPOSE: The present multicenter phase II trial investigated the combination of TACE and sorafenib for the treatment of HCC. PATIENTS AND METHODS: Eligibility criteria included histologically confirmed, unresectable HCC beyond Milan criteria, no extrahepatic spread, Child-Pugh score ≤ 8 and ECOG PS 0-2. Patients had received no prior therapy for HCC. Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE). TACE with lipiodol, 50 mg doxorubicin and polyvinyl alcohol (PVA) particles was repeated q6w as long as there was no overall disease progression. Tumor assessment by MRI was performed q6w according to EASL criteria. The primary endpoint was time to progression (TTP). RESULTS: Patients (n = 43) received a mean of 2.6 ± 2.2 TACE interventions (range 0-10). Median TTP was 16.4 months (95 % CI 10.7-∞). Median overall survival (OS) was 20.1 months (95 % CI 17.6-28.2). Disease control rate according to EASL criteria was 74.4 % (7 % complete responses [CRs] + 41.8 % partial responses [PRs] + 25.6 % stable diseases [SDs]). Four patients (9 %) became amenable to either radiofrequency ablation or liver transplantation; 5 (12 %) patients died during the trial. Overall, there were 360 AEs, including 56 grade 3/4 AEs and 39 SAEs. CONCLUSIONS: Combination treatment of TACE and sorafenib in the present trial was tolerable and associated with an interesting response rate, TTP and OS. Combination therapies will probably close gaps in the present mono therapy driven treatment guidelines for locally advanced HCC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic/methods , Liver Neoplasms/therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Ascites/etiology , Chemoembolization, Therapeutic/adverse effects , Combined Modality Therapy , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Ethiodized Oil/administration & dosage , Ethiodized Oil/adverse effects , Fatigue/etiology , Hepatic Encephalopathy/etiology , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Niacinamide/administration & dosage , Niacinamide/analogs & derivatives , Phenylurea Compounds/administration & dosage , Sorafenib , Treatment Outcome
5.
Eur J Intern Med ; 25(5): 430-7, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24666568

ABSTRACT

Hepatocellular carcinoma (HCC) represents the most common liver cancer with an increasing incidence and it accounts for the third most common cause of cancer-related death worldwide. Even though the clinical diagnosis and management of HCC improved significantly in the last decades, this malignant disease is still associated with a poor prognosis. It has to be distinguished between patients with HCCs, which developed from liver cirrhosis, and patients without underlying liver cirrhosis as classification systems, prognosis estimation and therapy recommendations differ in-between. In case of HCC in patients with liver cirrhosis in Europe, treatment allocation and prognosis estimation are mainly based on the Barcelona-Clinic Liver Cancer (BCLC) staging system. Based on this staging system different surgical, interventional radiological/sonographical and non-interventional procedures have been established for the multimodal treatment of HCC. The BCLC classification system represents a decision guidance; however because of its limitations in selected patients treatment allocation should be determined on an individualized rather than a guideline-based medicine by a multidisciplinary board in order to offer the best treatment option for each patient. This review summarizes the current management of HCC and illustrates controversial areas of therapeutic strategies.


Subject(s)
Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/radiotherapy , Carcinoma, Hepatocellular/surgery , Catheter Ablation , Chemoembolization, Therapeutic , Combined Modality Therapy , Humans , Hyperthermia, Induced , Liver Cirrhosis/complications , Liver Neoplasms/complications , Liver Neoplasms/pathology , Liver Neoplasms/radiotherapy , Liver Neoplasms/surgery , Liver Transplantation , Microwaves , Neoplasm Staging , Prognosis
6.
Neuroimage ; 61(1): 216-27, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22405731

ABSTRACT

Visual attention is associated with occipital gamma band activity. While gamma band power can be modulated by attention, the frequency of gamma band activity is known to decrease with age. The present study tested the hypothesis that reduced visual attention is associated with a change in induced gamma band activity. To this end, 26 patients with liver cirrhosis and 8 healthy controls were tested. A subset of patients showed symptoms of hepatic encephalopathy (HE), a frequent neuropsychiatric complication in liver disease, which comprises a gradual increase of cognitive dysfunction including attention deficits. All participants completed a behavioral task requiring shifts of attention between simultaneously presented visual and auditory stimuli. Brain activity was recorded using magnetoencephalography (MEG). The individual critical flicker frequency (CFF) was assessed as it is known to reliably reflect the severity of HE. Results showed correlations of behavioral data and HE severity, as indexed by CFF. Individual visual gamma band peak frequencies correlated positively with the CFF (r=0.41). Only participants with normal, but not with pathological CFF values showed a modulation of gamma band power with attention. The present results suggest that CFF and attentional performance are related. Moreover, a tight relation between the CFF and occipital gamma band activity both in frequency and power is shown. Thus, the present study provides evidence that a reduced CFF in HE, a disease associated with attention deficits, is closely linked to a slowing of gamma band activity and impaired modulation of gamma band power in a bimodal attention task.


Subject(s)
Attention/physiology , Electroencephalography , Flicker Fusion/physiology , Acoustic Stimulation , Adult , Aged , Behavior/physiology , Data Interpretation, Statistical , Female , Hepatic Encephalopathy/physiopathology , Hepatic Encephalopathy/psychology , Humans , Individuality , Liver Cirrhosis/complications , Liver Cirrhosis/psychology , Magnetoencephalography , Male , Middle Aged , Neuropsychological Tests , Photic Stimulation , Psychomotor Performance/physiology , Reaction Time/physiology
7.
Mol Cancer Ther ; 9(5): 1378-95, 2010 May.
Article in English | MEDLINE | ID: mdl-20442308

ABSTRACT

The present studies determine in greater detail the molecular mechanisms upstream of the CD95 death receptor by which geldanamycin heat shock protein 90 inhibitors and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) inhibitors interact to kill carcinoma cells. MEK1/2 inhibition enhanced 17-allylamino-17-demethoxygeldanamycin (17AAG) toxicity that was suppressed in cells deleted for mutant active RAS that were nontumorigenic but was magnified in isogenic tumorigenic cells expressing Harvey RAS V12 or Kirsten RAS D13. MEK1/2 inhibitor and 17AAG treatment increased intracellular Ca(2+) levels and reduced GRP78/BiP expression in a Ca(2+)-dependent manner. GRP78/BiP overexpression, however, also suppressed drug-induced intracellular Ca(2+) levels. MEK1/2 inhibitor and 17AAG treatment increased reactive oxygen species (ROS) levels that were blocked by quenching Ca(2+) or overexpression of GRP78/BiP. MEK1/2 inhibitor and 17AAG treatment activated CD95 and inhibition of ceramide synthesis; ROS or Ca(2+) quenching blocked CD95 activation. In SW620 cells that are patient matched to SW480 cells, MEK1/2 inhibitor and 17AAG toxicity was significantly reduced, which correlated with a lack of CD95 activation and lower expression of ceramide synthase 6 (LASS6). Overexpression of LASS6 in SW620 cells enhanced drug-induced CD95 activation and enhanced tumor cell killing. Inhibition of ceramide signaling abolished drug-induced ROS generation but not drug-induced cytosolic Ca(2+) levels. Thus, treatment of tumor cells with MEK1/2 inhibitor and 17AAG induces cytosolic Ca(2+) and loss of GRP78/BiP function, leading to de novo ceramide synthesis pathway activation that plays a key role in ROS generation and CD95 activation.


Subject(s)
Apoptosis/drug effects , Benzoquinones/pharmacology , Calcium/pharmacology , Carcinoma/pathology , Gastrointestinal Neoplasms/pathology , Heat-Shock Proteins/physiology , Lactams, Macrocyclic/pharmacology , Protein Kinase Inhibitors/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Benzoquinones/administration & dosage , Calcium/metabolism , Carcinoma/metabolism , Ceramides/metabolism , Down-Regulation/drug effects , Drug Evaluation, Preclinical , Drug Interactions , Endoplasmic Reticulum Chaperone BiP , Gastrointestinal Neoplasms/metabolism , HCT116 Cells , Heat-Shock Proteins/antagonists & inhibitors , Heat-Shock Proteins/metabolism , Hep G2 Cells , Humans , Lactams, Macrocyclic/administration & dosage , MAP Kinase Kinase 1/antagonists & inhibitors , MAP Kinase Kinase 2/antagonists & inhibitors , Protein Kinase Inhibitors/administration & dosage , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Tumor Cells, Cultured
8.
Cell Physiol Biochem ; 24(3-4): 291-306, 2009.
Article in English | MEDLINE | ID: mdl-19710544

ABSTRACT

Hepatic encephalopathy (HE) in chronic liver disease is characterized by neuropsychiatric and motor disturbances and associated with a net increase of inhibitory neurotransmission. Though many studies, mostly carried out in animal models, have linked dysfunctions of single neurotransmitter systems with the pathogenesis of HE, reports concerning neurotransmitter receptor alterations are controversial. Little is known about the situation in humans. We carried out a multireceptor assessment of HE-associated changes in neurotransmitter receptor densities and affinities in human post-mortem brain samples. Dissociation constants and densities of different binding sites for glutamate, GABA, acetylcholine, norepinephrine, serotonin, dopamine and adenosine were determined by in vitro binding assays and quantitative receptor autoradiography in the motor cortex and putamen of HE and control brains. HE cases do not build a homogeneous group, but differ concerning direction and intensity of binding site density divergences from control values. The acetylcholine M2 binding site dissociation constant was significantly higher in HE brains. Nicotinic acetylcholine and adenosine type 1 and 2A densities were significantly down-regulated in the putamen of HE brains. Our data suggest that neurotransmitter alterations are probably not the primary key factor responsible for the neuropsychiatric and motor disturbances associated with HE.


Subject(s)
Basal Ganglia/physiopathology , Hepatic Encephalopathy/physiopathology , Motor Cortex/metabolism , Motor Cortex/physiopathology , Receptors, Neurotransmitter/metabolism , Acetylcholine/metabolism , Adenosine/metabolism , Adult , Aged , Autoradiography , Binding Sites , Case-Control Studies , Dopamine/metabolism , Fatal Outcome , Female , Glutamic Acid/metabolism , Humans , Liver Cirrhosis/metabolism , Liver Cirrhosis, Alcoholic/metabolism , Male , Middle Aged , Norepinephrine/metabolism , Protein Binding , Serotonin/metabolism , gamma-Aminobutyric Acid/metabolism
9.
Biol Chem ; 390(3): 235-44, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19090727

ABSTRACT

Members of all three classes of the protein kinase C (PKC) family including atypical PKCzeta (PKCzeta) are involved in central functions of liver parenchymal cells. However, expression and localization of PKCiota (PKCiota), the highly homologous atypical PKC (aPKC) isoform, in hepatocytes is unknown to date. PKCzeta and PKCiota were cloned from human and rat liver and fused to fluorescent protein tags (YFP). The sequence of full-length rat PKCiota is not yet known and was cloned from cDNA of hepatocytes by the use of degenerated primers. PKCzeta-YFP and PKCiota-YFP (human and rat) were expressed in HeLa or HEK293 cells and used to test the specificity of seven aPKC antibodies. Two antibodies were PKCiota-specific and two were specific for PKCzeta in immunofluorescence and Western blot analysis. Subcellular localization was analyzed by immunofluorescence in isolated rat and human hepatocytes and liver sections. Low immunoreactivity for aPKCs was found at the sinusoidal membrane and in the cytosol. The highest density of PKCiota as well as PKCzeta was found at the canalicular membrane in co-localization with ABC-transporters, such as bile salt export pump or multidrug resistance-associated protein 2. This topology suggests a specific function of aPKCs at the canalicular membrane in addition to their known role in cell polarity of epithelial cells.


Subject(s)
Isoenzymes/metabolism , Liver/enzymology , Protein Kinase C/metabolism , Amino Acid Sequence , Animals , Antibody Specificity , Base Sequence , Cloning, Molecular , DNA Primers , DNA, Complementary , Humans , Isoenzymes/chemistry , Isoenzymes/genetics , Liver/cytology , Molecular Sequence Data , Protein Kinase C/chemistry , Protein Kinase C/genetics , Rats , Sequence Homology, Amino Acid
10.
N Engl J Med ; 359(4): 378-90, 2008 Jul 24.
Article in English | MEDLINE | ID: mdl-18650514

ABSTRACT

BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. CONCLUSIONS: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)


Subject(s)
Benzenesulfonates/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Pyridines/therapeutic use , raf Kinases/antagonists & inhibitors , Aged , Benzenesulfonates/adverse effects , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/surgery , Chemotherapy, Adjuvant , Disease Progression , Double-Blind Method , Female , Humans , Liver Neoplasms/mortality , Liver Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Niacinamide/analogs & derivatives , Phenylurea Compounds , Proportional Hazards Models , Protein Kinase Inhibitors/adverse effects , Pyridines/adverse effects , Sorafenib , Survival Analysis
11.
Parasitol Res ; 100(4): 747-8, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17004096

ABSTRACT

Cerebral malaria, the most frequent complication of falciparum malaria, is usually predicted by an increased count of asexual parasites in peripheral blood. We report a case of a female returnee from Ghana who developed cerebral malaria in spite of parasite clearance in peripheral blood after therapy with atovaquone/proguanil.


Subject(s)
Antimalarials/therapeutic use , Atovaquone/therapeutic use , Malaria, Cerebral/drug therapy , Malaria, Cerebral/parasitology , Plasmodium falciparum/drug effects , Proguanil/therapeutic use , Adult , Animals , Artemisinins/therapeutic use , Artesunate , Female , Humans , Plasmodium falciparum/isolation & purification , Quinine/therapeutic use , Sesquiterpenes/therapeutic use
12.
Ann N Y Acad Sci ; 1043: 718-24, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16037298

ABSTRACT

Glycation of liver proteins by reactive aldehydes formed from the metabolism of ethanol and lipid peroxidation has been implicated in the development of both alcoholic and nonalcoholic liver cirrhosis. Modified proteins are targeted to the proteasome for proteolysis. Release of glycation-free adducts into the circulation may provide a diagnostic "signature" of hepatic protein damage. We quantitatively screened protein glycation, oxidation, and nitrosation adduct residues and free adducts in portal, hepatic, and peripheral venous blood plasma of cirrhotic patients; we also screened the hepatic and peripheral venous blood plasma of control subjects by liquid chromatography-mass spectrometry. There was a remarkable 14-16-fold increase of glyoxal-derived, hydroimidazolone-free adduct in portal and hepatic venous plasma of cirrhotic patients with respect to normal controls. There was only a twofold increase of glycation adduct residues in plasma proteins in cirrhotic patients, which was attributed mainly to decreased albumin turnover. Therapeutic strategies to decrease dicarbonyl compounds may be beneficial, such as dicarbonyl scavengers, glutathione repleting agents, and high-dose thiamine therapy.


Subject(s)
Blood Proteins/metabolism , Glycation End Products, Advanced/blood , Liver Cirrhosis/blood , Blood Proteins/antagonists & inhibitors , Glycosylation , Humans , Reference Values
13.
Med Klin (Munich) ; 98(12): 692-9, 2003 Dec 15.
Article in German | MEDLINE | ID: mdl-14685670

ABSTRACT

Despite impressive success of highly active antiretroviral therapy, a durable control of viral replication cannot be achieved in a substantial proportion of HIV-infected patients. The most important reason is development of resistance, defined as capability of mutant virus to replicate in the presence of a higher concentration of substance in comparison to wild-type virus. In the treated HIV-positive population resistance is prevalent in almost 50%, whereas in treatment-naïve resistance can be found in 10-14%. For diagnosis, genotypic resistance tests (sequencing of pol gene) and phenotypic resistance assays (susceptibility against antiretrovirals of an isolate in vitro) are available. A special problem is the interpretation of complex mutation patterns. Elaborate databases are implemented for this task. A number of clinical studies have demonstrated the value of resistance testing in the situation of virological failure. Resistance-guided salvage therapy was significantly more effective in these trials in comparison to former standard of care. This led to the recommendation of resistance testing in this clinical situation by German and international expert panels.


Subject(s)
Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Drug Resistance, Viral , HIV Infections/drug therapy , HIV/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Reverse Transcriptase Inhibitors/therapeutic use , Clinical Trials as Topic , Drug Resistance, Viral/genetics , Genotype , HIV/genetics , HIV Infections/virology , Humans , Microbial Sensitivity Tests , Multivariate Analysis , Mutation , Phenotype , Prospective Studies , Viral Load
14.
Arch Biochem Biophys ; 413(1): 32-40, 2003 May 01.
Article in English | MEDLINE | ID: mdl-12706339

ABSTRACT

The effect of oral taurine supplementation on endotoxin-induced cholestasis was investigated in rat liver. At 12h following lipopolysaccharide (LPS) injection (4mg/kg body weight i.p.) bile flow and bromosulfophthalein (BSP) and taurocholate (TC) excretion were determined in the perfused liver and the expression of the canalicular transporters multidrug resistance protein 2 (Mrp2) and bile salt export pump (Bsep) was analyzed. Injection of LPS induced a significant decrease of bile flow ( 2.2+/-0.2 microl/g liver wet weight/min vs 3.3+/-0.1 microl/g liver wet weight in controls), biliary BSP excretion (10.8+/-2.2 nmol/g/min vs 21.0+/-3.8 nmol/g/min), and biliary TC excretion (114+/-23 nmol/g/min vs 228+/-8 nmol/g/min). These effects were due to transporter retrieval from the canalicular membrane and downregulation of Mrp2 and Bsep expression. In taurine-supplemented rats bile flow was 30% higher than that in untreated rats and the expression of Mrp2 and Bsep protein was increased two- to threefold. In taurine-supplemented rats there was no significant reduction of bile flow or of BSP and TC excretion at 12h following LPS injection. This protective effect of taurine was due to higher Mrp2 and Bsep protein levels compared to nonsupplemented LPS-treated rats, whereas relative Mrp2 retrieval from the canalicular membrane induced by LPS was not significantly different. LPS-induced tumor necrosis factor alpha and interleukin-1beta release were lower in taurine-fed rats; however, downregulation of Mrp2 and Bsep expression by LPS was delayed but not prevented. The data show that oral supplementation of taurine induces Mrp2 and Bsep expression and may prevent LPS-induced cholestasis.


Subject(s)
ATP-Binding Cassette Transporters/biosynthesis , ATP-Binding Cassette Transporters/genetics , Bile Acids and Salts/metabolism , Carrier Proteins/biosynthesis , Cholestasis/prevention & control , Taurine/administration & dosage , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Animals , Biological Transport, Active/drug effects , Carrier Proteins/genetics , Cholestasis/chemically induced , Gene Expression/drug effects , In Vitro Techniques , Interleukin-1/metabolism , Lipopolysaccharides/toxicity , Liver/drug effects , Liver/physiology , Male , Pregnane X Receptor , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Steroid/metabolism , Subcellular Fractions/metabolism , Tumor Necrosis Factor-alpha/metabolism
15.
Liver ; 22(6): 474-8, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12445172

ABSTRACT

BACKGROUND: There is increasing evidence for an interaction between iron and copper metabolism. METHODS: Iron indices (ferritin, transferrin saturation [TS], serum iron), liver parameters, the prevalence and significance of C282Y and H63D HFE mutations were studied in 40 unrelated, Caucasian patients with Wilson's disease and 295 healthy controls. Due to specific treatment Wilson's disease was well controlled in all but one patient. RESULTS: The allele frequencies for the C282Y (11.3% vs. 6.2%) and the H63D (18.8% vs. 16.4%) mutation did not differ between patients with Wilson's disease and healthy controls. One patient with C282Y homozygous HH and Wilson's disease was identified showing progressive liver disease despite reasonable venesection and copper chelation therapy. No differences in iron indices and liver values were seen between HFE heterozygous and HFE wildtype patients with Wilson's disease. Higher serum ferritin levels were noticed in patients with Wilson's disease compared to healthy controls (149 +/- 26 microg/l vs. 87 +/- 8 microg/l; P < 0.03). CONCLUSIONS: It appears reasonable to assess iron indices in patients with Wilson's disease in order to detect iron overload. HFE mutations other than C282Y homozygosity seem to have no impact on iron indices and liver parameters as long as Wilson's disease is controlled.


Subject(s)
Hepatolenticular Degeneration/genetics , Histocompatibility Antigens Class I/genetics , Iron/metabolism , Membrane Proteins/genetics , Adolescent , Adult , Aged , Child , DNA/analysis , DNA Mutational Analysis , Female , Ferritins/blood , Gene Frequency , Hemochromatosis Protein , Hepatolenticular Degeneration/metabolism , Hepatolenticular Degeneration/therapy , Histocompatibility Antigens Class I/metabolism , Homozygote , Humans , Iron/analysis , Male , Membrane Proteins/metabolism , Middle Aged , Mutation , Reference Values , Transferrin/analysis
16.
Arch Biochem Biophys ; 401(2): 187-97, 2002 May 15.
Article in English | MEDLINE | ID: mdl-12054469

ABSTRACT

The expression of sodium potassium chloride cotransporter 1 (NKCC1) was studied in different liver cell types. NKCC1 was found in rat liver parenchymal and sinusoidal endothelial cells and in human HuH-7 hepatoma cells. NKCC1 expression in rat hepatic stellate cells increased during culture-induced transformation in the myofibroblast-like phenotype. NKCC1 inhibition by bumetanide increased alpha(1)-smooth muscle actin expression in 2-day-cultured hepatic stellate cells but was without effect on basal and platelet-derived-growth-factor-induced proliferation of the 14-day-old cells. In perfused rat liver the NKCC1 made a major contribution to volume-regulatory K(+) uptake induced by hyperosmolarity. Long-term hyperosmotic treatment of HuH-7 cells by elevation of extracellular NaCl or raffinose concentration but not hyperosmotic urea or mannitol profoundly induced NKCC1 mRNA and protein expression. This was antagonized by the compatible organic osmolytes betaine or taurine. The data suggest a role of NKCC1 in stellate cell transformation, hepatic volume regulation, and long-term adaption to dehydrating conditions.


Subject(s)
Liver/metabolism , Sodium-Potassium-Chloride Symporters/genetics , Sodium-Potassium-Chloride Symporters/metabolism , Animals , Base Sequence , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Cell Division/drug effects , Cell Size , DNA, Complementary/genetics , Gene Expression , Humans , In Vitro Techniques , Liver/cytology , Liver/drug effects , Male , Osmolar Concentration , Perfusion , Platelet-Derived Growth Factor/pharmacology , Potassium/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Sodium Potassium Chloride Symporter Inhibitors , Solute Carrier Family 12, Member 2 , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL